Previous 10 | Next 10 |
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 PR Newswire Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-...
2024-03-26 05:51:00 ET Some investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus Pharmaceuticals several years ago. They'll probably also recall that the initial euphoria over those drugs quickly faded. This time it's different. The commercial success ...
2024-03-24 23:25:36 ET Summary The rate of rise for big-cap tech stocks is slowing down or losing altitude, suggesting it may not be the best time to invest in them. The economy is growing, inflation is under control, and the Fed is committed to cutting rates, creating opportuniti...
2024-03-24 09:15:00 ET There's no shortage of hype and excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock these days. The company has a promising weight loss drug candidate in its pipeline at a time when many healthcare businesses are eager to get a piece of that massiv...
2024-03-23 05:53:00 ET Viking Therapeutics (NASDAQ: VKTX) now ranks among the hottest biotech stocks on the market. The company's announcement in February of positive results from its phase 2 study of experimental weight loss drug VK2735 provided a huge catalyst. The future for ...
2024-03-22 04:55:00 ET Eli Lilly (NYSE: LLY) has become a giant in what may be a $100 billion market a few years from now. I'm talking about the world of weight loss drugs. Doctors have been prescribing Mounjaro and the newly approved Zepbound to patients aiming to shed pounds, ...
2024-03-21 08:49:21 ET There are potential share price gains, and then there are potential share price gains . In the view of one analyst, Viking Therapeutics (NASDAQ: VKTX) currently stands in front of the latter variety. The clinical-stage biotech recently came into sharp ...
2024-03-19 10:16:19 ET Summary Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows. Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations ...
2024-03-19 09:45:00 ET Viking Therapeutics ' (NASDAQ: VKTX) stock is up an eye-popping 860% over the last three years, with the lion's share of those gains occurring in the last few months. The biotech's pursuit of treatments for metabolic illnesses like obesity shows no sign of slo...
2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-20 06:00:00 ET California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Three Motley Fool contributors think they've found bi...
2024-07-19 05:50:00 ET Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally, the company would have a pipeline featuring multiple promising candid...
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 PR Newswire Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO , July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc...